Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Nemolizumab therapy showed continuous improvements in atopic dermatitis symptoms up to 56 weeks, with 47% achieving clear or almost clear skin and 73% improving EASI scores by 75%. Nemolizumab, an IL-31 receptor antagonist, demonstrated a favorable safety profile with no unexpected adverse events, positioning it as a valuable long-term treatment option for atopic dermatitis.
Sanofi, Regeneron get USFDA nod for Dupixent for COPD
The FDA approved Sanofi's Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, marking the first biologic medicine for these patients. Dupixent demonstrated a 30-34% reduction in annualized moderate or severe COPD exacerbations, improved lung function, and enhanced quality of life in phase 3 studies.
FDA Approves Dupixent for Patients with COPD
FDA approves Dupixent as add-on treatment for adults with uncontrolled COPD, marking the first biologic therapy for this condition. Dupixent, developed by Sanofi and Regeneron, targets type 2 inflammation pathways and has shown efficacy in reducing COPD exacerbations and improving lung function in phase 3 trials. The drug also has other approved uses and is being studied for bullous pemphigoid.
Dupixent approved in the US as the first-ever biologic medicine for patients
Dupixent approved by FDA as the first biologic medicine for adults with inadequately controlled COPD and an eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improvements in lung function, and health-related quality of life.
FDA Approves Dupixent as First-Ever Biologic Treatment for Chronic Obstructive Pulmonary Disease
FDA approves Regeneron and Sanofi’s Dupixent as the first biologic treatment for adults with eosinophilic COPD, based on Phase III BOREAS and NOTUS trials showing significant reduction in exacerbations and improved lung function. Dupixent also improved quality of life and had a consistent safety profile.
FDA greenlights Regeneron's Dupixent for the treatment of COPD
FDA approves Regeneron and Sanofi's Dupixent for COPD, making it the first biologic treatment for the condition. Dupixent, an interleukin-4 receptor alpha antagonist, showed reduced exacerbations and improved lung function in Phase III studies. The approval follows failures of GSK's Nucala and AstraZeneca's Fasenra in COPD trials.
Related Clinical Trials:
Sanofi/Regeneron's Dupixent set to dominate COPD biologics market following FDA approval
FDA approves Sanofi and Regeneron’s Dupixent for COPD, showing significant reduction in exacerbations and improved lung function in Phase III trials. Expected to dominate COPD biologics market with projected sales of $6.57bn by 2033.
Sanofi/Regeneron's Dupixent set to dominate COPD biologics market share following FDA approval
FDA approves Sanofi/Regeneron’s Dupixent as first biologic for uncontrolled COPD, following EMA approval. Dupixent targets IL4 and IL13 pathways, reducing exacerbations and improving lung function. GlobalData forecasts $6.57 billion in sales by 2033.
Sanofi's dupixent approved in the US as the first-ever biologic medicine for patients with COPD
The FDA approves Sanofi’s Dupixent as the first biologic medicine for adults with inadequately controlled COPD and an eosinophilic phenotype, offering potential for improved breathing and fewer exacerbations.
Sanofi and Regeneron's Dupixent Snags First Biologic Approval in COPD
Sanofi and Regeneron's Dupixent is the first biologic approved in the U.S. for COPD, potentially benefiting 300,000 adults with poorly controlled disease. Dupixent showed a 30-34% reduction in COPD exacerbations in Phase III studies and is consistent with existing safety profiles. The approval adds to Dupixent's list of FDA-approved indications, including asthma and eczema, with anticipated sales of $3.5 billion from the COPD approval. Competitors like GSK, AstraZeneca, and Amgen are also developing treatments for COPD.
© Copyright 2024. All Rights Reserved by MedPath